Randomized controlled trial of memantine in dementia associated with Parkinson's disease
Identifieur interne : 000975 ( Main/Exploration ); précédent : 000974; suivant : 000976Randomized controlled trial of memantine in dementia associated with Parkinson's disease
Auteurs : Iracema Leroi [Royaume-Uni] ; Ross Overshott [Royaume-Uni] ; E. Jane Byrne [Royaume-Uni] ; Emily Daniel [Royaume-Uni] ; Alistair Burns [Royaume-Uni]Source :
- Movement Disorders [ 0885-3185 ] ; 2009-06-15.
English descriptors
Abstract
The objective of this study is to investigate the safety and tolerability of memantine, a glutamatergic modulator, in patients suffering from dementia associated with Parkinson's disease (PDD), an increasingly common complication of PD. This was a 22‐week trial of 25 participants with a DSM‐IV diagnosis of PDD who were randomized to either placebo or 20 mg/day of memantine. Memantine was well tolerated by participants at 20 mg/day dosing. No participant was withdrawn due to memantine‐related adverse events. Six weeks after drug withdrawal, a significantly greater proportion (P = 0.04) of memantine‐treated participants deteriorated globally compared with those treated with placebo. These findings suggest that continued treatment with memantine may be needed to maintain global level of functioning over time. Based on the findings of this pilot study, memantine is safe and very well‐tolerated in PDD. © 2009 Movement Disorder Society
Url:
DOI: 10.1002/mds.22495
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Randomized controlled trial of memantine in dementia associated with Parkinson's disease</title><author><name sortKey="Leroi, Iracema" sort="Leroi, Iracema" uniqKey="Leroi I" first="Iracema" last="Leroi">Iracema Leroi</name></author><author><name sortKey="Overshott, Ross" sort="Overshott, Ross" uniqKey="Overshott R" first="Ross" last="Overshott">Ross Overshott</name></author><author><name sortKey="Byrne, E Jane" sort="Byrne, E Jane" uniqKey="Byrne E" first="E. Jane" last="Byrne">E. Jane Byrne</name></author><author><name sortKey="Daniel, Emily" sort="Daniel, Emily" uniqKey="Daniel E" first="Emily" last="Daniel">Emily Daniel</name></author><author><name sortKey="Burns, Alistair" sort="Burns, Alistair" uniqKey="Burns A" first="Alistair" last="Burns">Alistair Burns</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:F42C0AF5033E486E89180E197D6D72D45D077AFB</idno><date when="2009" year="2009">2009</date><idno type="doi">10.1002/mds.22495</idno><idno type="url">https://api.istex.fr/document/F42C0AF5033E486E89180E197D6D72D45D077AFB/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">003114</idno><idno type="wicri:Area/Main/Curation">002D17</idno><idno type="wicri:Area/Main/Exploration">000975</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Randomized controlled trial of memantine in dementia associated with Parkinson's disease</title><author><name sortKey="Leroi, Iracema" sort="Leroi, Iracema" uniqKey="Leroi I" first="Iracema" last="Leroi">Iracema Leroi</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Consultant in Old Age Psychiatry/Honorary Senior Lecturer, Lancashire Care Trust, Royal Blackburn Hospital, Blackburn</wicri:regionArea><wicri:noRegion>Blackburn</wicri:noRegion></affiliation><affiliation wicri:level="4"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Psychiatry and Behaviourial Sciences, University of Manchester, Manchester</wicri:regionArea><placeName><settlement type="city">Manchester</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Manchester</region></placeName><orgName type="university">Université de Manchester</orgName></affiliation></author><author><name sortKey="Overshott, Ross" sort="Overshott, Ross" uniqKey="Overshott R" first="Ross" last="Overshott">Ross Overshott</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Consultant in Psychological Medicine, Pennine Care NHS Foundation Trust, Royal Oldham Hospital, Rochdale</wicri:regionArea><wicri:noRegion>Rochdale</wicri:noRegion></affiliation></author><author><name sortKey="Byrne, E Jane" sort="Byrne, E Jane" uniqKey="Byrne E" first="E. Jane" last="Byrne">E. Jane Byrne</name><affiliation wicri:level="4"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Senior Lecturer in Old Age Psychiatry, University of Manchester, Manchester</wicri:regionArea><placeName><settlement type="city">Manchester</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Manchester</region></placeName><orgName type="university">Université de Manchester</orgName></affiliation></author><author><name sortKey="Daniel, Emily" sort="Daniel, Emily" uniqKey="Daniel E" first="Emily" last="Daniel">Emily Daniel</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Assistant Psychologist, Manchester Mental Health and Social Care Trust, Manchester</wicri:regionArea><placeName><settlement type="city">Manchester</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Manchester</region></placeName></affiliation></author><author><name sortKey="Burns, Alistair" sort="Burns, Alistair" uniqKey="Burns A" first="Alistair" last="Burns">Alistair Burns</name><affiliation wicri:level="4"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Professor of Old Age Psychiatry, University of Manchester, Manchester</wicri:regionArea><placeName><settlement type="city">Manchester</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Manchester</region></placeName><orgName type="university">Université de Manchester</orgName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2009-06-15">2009-06-15</date><biblScope unit="volume">24</biblScope><biblScope unit="issue">8</biblScope><biblScope unit="page" from="1217">1217</biblScope><biblScope unit="page" to="1221">1221</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">F42C0AF5033E486E89180E197D6D72D45D077AFB</idno><idno type="DOI">10.1002/mds.22495</idno><idno type="ArticleID">MDS22495</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease dementia</term><term>clinical trial</term><term>cognitive impairment</term><term>memantine</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The objective of this study is to investigate the safety and tolerability of memantine, a glutamatergic modulator, in patients suffering from dementia associated with Parkinson's disease (PDD), an increasingly common complication of PD. This was a 22‐week trial of 25 participants with a DSM‐IV diagnosis of PDD who were randomized to either placebo or 20 mg/day of memantine. Memantine was well tolerated by participants at 20 mg/day dosing. No participant was withdrawn due to memantine‐related adverse events. Six weeks after drug withdrawal, a significantly greater proportion (P = 0.04) of memantine‐treated participants deteriorated globally compared with those treated with placebo. These findings suggest that continued treatment with memantine may be needed to maintain global level of functioning over time. Based on the findings of this pilot study, memantine is safe and very well‐tolerated in PDD. © 2009 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>Royaume-Uni</li></country><region><li>Angleterre</li><li>Grand Manchester</li></region><settlement><li>Manchester</li></settlement><orgName><li>Université de Manchester</li></orgName></list><tree><country name="Royaume-Uni"><noRegion><name sortKey="Leroi, Iracema" sort="Leroi, Iracema" uniqKey="Leroi I" first="Iracema" last="Leroi">Iracema Leroi</name></noRegion><name sortKey="Burns, Alistair" sort="Burns, Alistair" uniqKey="Burns A" first="Alistair" last="Burns">Alistair Burns</name><name sortKey="Byrne, E Jane" sort="Byrne, E Jane" uniqKey="Byrne E" first="E. Jane" last="Byrne">E. Jane Byrne</name><name sortKey="Daniel, Emily" sort="Daniel, Emily" uniqKey="Daniel E" first="Emily" last="Daniel">Emily Daniel</name><name sortKey="Leroi, Iracema" sort="Leroi, Iracema" uniqKey="Leroi I" first="Iracema" last="Leroi">Iracema Leroi</name><name sortKey="Overshott, Ross" sort="Overshott, Ross" uniqKey="Overshott R" first="Ross" last="Overshott">Ross Overshott</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000975 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000975 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:F42C0AF5033E486E89180E197D6D72D45D077AFB
|texte= Randomized controlled trial of memantine in dementia associated with Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |